ZYG 24002
Alternative Names: ZYG-24002Latest Information Update: 17 Feb 2026
At a glance
- Originator Sinomune
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Seborrhoeic dermatitis
Most Recent Events
- 11 Feb 2026 Sinomune Pharmaceutical plans a phase I trial for Seborrhoeic dermatitis in China (Topical, Lotion) in February 2026 (NCT07404033) (CTR20260243)
- 11 Feb 2026 Preclinical trials in Seborrhoeic dermatitis in China (Topical)